Literature DB >> 26686431

Elevated Stroke Risk Associated With Femoral Artery Cannulation During Mitral Valve Surgery.

Kareem Bedeir1, Michael Reardon1, Mahesh Ramchandani1, Karanbir Singh1, Basel Ramlawi1.   

Abstract

Minimally invasive mitral valve (MV) surgery, often requiring femoral artery (FA) cannulation, is increasingly being adopted. There is concern about increased stroke rates associated with minimally invasive MV surgery. This study aims to examine whether FA cannulation is independently associated with increased stroke rates in minimally invasive MV procedures. MV procedures from January 2004 to June 2012 were reviewed using our institutional Society of Thoracic Surgeons database. We included 384 patients after the exclusion of patients with emergency procedures, with infective endocarditis, who underwent other concomitant procedures, who were older than 60 years, and with nonstandard aortic clamping (endoballoon or no clamp). Patients were divided into 2 groups: those who underwent aortic cannulation (n = 327) and those who underwent femoral cannulation (n = 57). Risk adjustments through multivariable regression were used to identify independent predictors for various outcomes. Adjustments were made for cardiopulmonary bypass and aortic clamp times. Preoperatively, the femoral cannulation group had less baseline cerebrovascular disease (P = 0.032), heart failure (P = 0.028), and atrial fibrillation (P = 0.012). Other baseline characteristics were similar. The aortic cannulation group had shorter cardiopulmonary bypass (P < 0.001) and clamp times (P < 0.001). There were more repairs done in the FA cannulation group as opposed to replacements. Risk-adjusted outcomes showed a higher incidence of permanent stroke in the femoral cannulation group (P = 0.032). Other outcomes were not significantly different. In conclusion, FA cannulation may be associated with increased stroke rates in isolated MV surgery. Antegrade arterial cannulation (direct aortic or axillary cannulation) may be preferable in minimally invasive MV procedures. Randomized trial data are needed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cannulation; cardiopulmonary bypass; minimally invasive cardiac surgery; mitral repair, stroke

Mesh:

Year:  2015        PMID: 26686431     DOI: 10.1053/j.semtcvs.2015.06.008

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  6 in total

Review 1.  Aortic Valve Surgery: Minimally Invasive Options.

Authors:  Basel Ramlawi; Kareem Bedeir; Joseph Lamelas
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Jan-Mar

2.  Impact of standardized computed tomographic angiography for minimally invasive mitral and tricuspid valve surgery.

Authors:  Moritz B Immohr; Yukiharu Sugimura; Patric Kröpil; Hug Aubin; Jan-Philipp Minol; Alexander Albert; Udo Boeken; Artur Lichtenberg; Payam Akhyari
Journal:  J Cardiothorac Surg       Date:  2021-03-20       Impact factor: 1.637

3.  Peripheral vascular complications following totally endoscopic cardiac surgery.

Authors:  Ling-Chen Huang; Qi-Chen Xu; Dao-Zhong Chen; Xiao-Fu Dai; Liang-Wan Chen
Journal:  J Cardiothorac Surg       Date:  2021-03-20       Impact factor: 1.637

4.  Aortic Valve Replacement Via Right Anterior Mini-Thoracotomy: the Conventional Procedure Performed Through a Smaller Incision.

Authors:  Gabriele Tamagnini; Raoul Biondi; Mauro Del Giglio
Journal:  Braz J Cardiovasc Surg       Date:  2021-02-01

5.  Open Seldinger-guided peripheral femoro-femoral cannulation technique for totally endoscopic cardiac surgery.

Authors:  Yi Chen; Liang-Wan Chen; Xiao-Fu Dai; Xue-Shan Huang
Journal:  J Cardiothorac Surg       Date:  2021-07-22       Impact factor: 1.637

6.  Early and long-term results of minimally invasive mitral valve surgery through a right mini-thoracotomy approach: a retrospective propensity-score matched analysis.

Authors:  Sabreen Mkalaluh; Marcin Szczechowicz; Bashar Dib; Anton Sabashnikov; Gabor Szabo; Matthias Karck; Alexander Weymann
Journal:  PeerJ       Date:  2018-05-28       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.